SG11201806855WA - Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine - Google Patents
Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabineInfo
- Publication number
- SG11201806855WA SG11201806855WA SG11201806855WA SG11201806855WA SG11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA
- Authority
- SG
- Singapore
- Prior art keywords
- medivir
- box
- international
- huddinge
- troxacitabine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650274 | 2016-03-02 | ||
| SE1651204 | 2016-09-08 | ||
| PCT/SE2017/050186 WO2017151044A1 (fr) | 2016-03-02 | 2017-02-28 | Traitement d'association utilisant du sorafénib ou du régorafénib et un promédicament de la troxacitabine de type phosphoramidate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806855WA true SG11201806855WA (en) | 2018-09-27 |
Family
ID=59744330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806855WA SG11201806855WA (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10456413B2 (fr) |
| EP (1) | EP3423061A4 (fr) |
| JP (1) | JP6968080B2 (fr) |
| KR (1) | KR20180118745A (fr) |
| CN (2) | CN109069509B (fr) |
| AU (2) | AU2017227516B2 (fr) |
| CA (1) | CA3014769C (fr) |
| RU (1) | RU2018134336A (fr) |
| SG (1) | SG11201806855WA (fr) |
| WO (1) | WO2017151044A1 (fr) |
| ZA (1) | ZA201805445B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3423061A4 (fr) | 2016-03-02 | 2019-11-13 | Medivir Aktiebolag | Traitement d'association utilisant du sorafénib ou du régorafénib et un promédicament de la troxacitabine de type phosphoramidate |
| JP2021512875A (ja) * | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 細胞免疫療法の組み合わせ |
| EP3927347B1 (fr) * | 2019-02-18 | 2023-12-27 | Medivir Aktiebolag | Méthodes de traitement de cancers du foie à l'aide de nucléotide de dioxolane administré par voie orale en combinaison avec un anticorps monoclonal anti-pd1 ou anti-pdl1 |
| CN115485029A (zh) * | 2020-04-15 | 2022-12-16 | 美迪维尔公司 | 用于肝癌的miv-818/乐伐替尼组合疗法 |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
| IT202000022636A1 (it) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1324997A2 (fr) * | 2000-10-13 | 2003-07-09 | Shire Biochem Inc. | Analogues de dioxolane pour administration intercellulaire amelioree |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| JP4860474B2 (ja) | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素 |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| EP2591775A1 (fr) * | 2006-04-05 | 2013-05-15 | Novartis AG | Combinaisons comprenant des inhibiteurs de mTOR pour le traitement du cancer |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| CN102190616B (zh) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| RU2019126908A (ru) | 2012-04-13 | 2020-01-13 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| CN103570613B (zh) | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | 氘代ω-二苯基脲或其盐的多晶型物 |
| US8969388B1 (en) | 2012-07-28 | 2015-03-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
| WO2014047199A1 (fr) * | 2012-09-19 | 2014-03-27 | The Research Foundation For The State University Of New York | Nouveaux promédicaments pour une thérapie anticancéreuse sélective |
| AU2014354775A1 (en) * | 2013-11-27 | 2016-05-19 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
| US20170198005A1 (en) * | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| MX369649B (es) * | 2014-08-25 | 2019-11-15 | Medivir Ab | Analogos de dioxolano de uridina para el tratamiento del cancer. |
| EP3423061A4 (fr) * | 2016-03-02 | 2019-11-13 | Medivir Aktiebolag | Traitement d'association utilisant du sorafénib ou du régorafénib et un promédicament de la troxacitabine de type phosphoramidate |
-
2017
- 2017-02-28 EP EP17760400.6A patent/EP3423061A4/fr active Pending
- 2017-02-28 JP JP2018545847A patent/JP6968080B2/ja active Active
- 2017-02-28 KR KR1020187028361A patent/KR20180118745A/ko active IP Right Grant
- 2017-02-28 CN CN201780014430.0A patent/CN109069509B/zh active Active
- 2017-02-28 US US16/081,383 patent/US10456413B2/en active Active
- 2017-02-28 WO PCT/SE2017/050186 patent/WO2017151044A1/fr active Application Filing
- 2017-02-28 CN CN202010727607.5A patent/CN111956646B/zh active Active
- 2017-02-28 CA CA3014769A patent/CA3014769C/fr active Active
- 2017-02-28 SG SG11201806855WA patent/SG11201806855WA/en unknown
- 2017-02-28 AU AU2017227516A patent/AU2017227516B2/en active Active
- 2017-02-28 RU RU2018134336A patent/RU2018134336A/ru not_active Application Discontinuation
-
2018
- 2018-08-15 ZA ZA2018/05445A patent/ZA201805445B/en unknown
-
2019
- 2019-08-30 US US16/557,511 patent/US10960017B2/en active Active
-
2022
- 2022-06-01 AU AU2022203761A patent/AU2022203761B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6968080B2 (ja) | 2021-11-17 |
| US10960017B2 (en) | 2021-03-30 |
| AU2022203761B2 (en) | 2024-06-13 |
| US20190091246A1 (en) | 2019-03-28 |
| RU2018134336A3 (fr) | 2020-05-22 |
| AU2017227516A1 (en) | 2018-08-30 |
| AU2017227516B2 (en) | 2022-03-03 |
| CA3014769A1 (fr) | 2017-09-08 |
| CN111956646B (zh) | 2023-07-25 |
| RU2018134336A (ru) | 2020-04-02 |
| CA3014769C (fr) | 2024-01-09 |
| JP2019507764A (ja) | 2019-03-22 |
| CN111956646A (zh) | 2020-11-20 |
| WO2017151044A1 (fr) | 2017-09-08 |
| CN109069509B (zh) | 2020-10-16 |
| AU2022203761A1 (en) | 2022-06-16 |
| ZA201805445B (en) | 2019-07-31 |
| CN109069509A (zh) | 2018-12-21 |
| BR112018067387A2 (pt) | 2019-01-02 |
| KR20180118745A (ko) | 2018-10-31 |
| EP3423061A4 (fr) | 2019-11-13 |
| US10456413B2 (en) | 2019-10-29 |
| EP3423061A1 (fr) | 2019-01-09 |
| US20200009166A1 (en) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806855WA (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804888WA (en) | Velocity model update with an inversion gradient | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201810268YA (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |